The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by ...

There’s no doubt that GLP-1 drugs like Ozempic have been revolutionary — although the benefits do sometimes come with some ...

Oxyntomodulin (OXM) is a peptide hormone released by intestinal L cells after food intake. It acts as a dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors, regulating appetite, ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18, offering both glycemic control and weight loss ...

USA: Researchers have found in a new study that patients with idiopathic intracranial hypertension (IIH) treated with ...

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...

People who use GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, or GERD, a new ...

Initially developed to treat type-2 diabetes, the drugs have more recently demonstrated a capacity to neutralize patients' ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...